NCT02787109View on ClinicalTrials.gov

Safety of Chlamydia Vaccine CTH522 in Healthy Women Aged 18 to 45 Years

PHASE1CompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

July 31, 2016

Primary Completion Date

July 31, 2017

Study Completion Date

July 31, 2017

Conditions
Chlamydia Trachomatis
Interventions
BIOLOGICAL

CTH522-CAF01

CTH522 chlamydia antigen adjuvanted with CAF01 for IM administration

BIOLOGICAL

CTH522-Al(OH)3

CTH522 chlamydia antigen adjuvanted with aluminium hydroxide, Al(OH)3 , for IM administration

BIOLOGICAL

Placebo

Saline

Trial Locations (1)

W12 0HS

NIHR/Wellcome Trust Imperial Clinical Research Facility, Hammersmith Hospital, London

All Listed Sponsors
collaborator

Imperial College London

OTHER

lead

Statens Serum Institut

OTHER

NCT02787109 - Safety of Chlamydia Vaccine CTH522 in Healthy Women Aged 18 to 45 Years | Biotech Hunter | Biotech Hunter